Voriconazole versus Micafungin for empirical antifungal therapy in patients with neutropenia and persistent fever

Voriconazole versus Micafungin for empirical antifungal therapy in patients with neutropenia and persistent fever - Voriconazole versus Micafungin in patients with FN

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000630

Enrollment

100

Registered

2008-12-31

Start date

2007-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

febril neutropenia

Interventions

Micafugin150mg iv once a day Voriconazole 6mg/kg iv twice a day on day1,followed by 4mg/kg iv twice daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)fever with tempreture above 38.0 degree. 2)neutropenia(<500cells/uL)for at least 4days. 3)injectable antibacterials for at least 4days.

Exclusion criteria

Exclusion criteria: 1)AST/ALT/total bilirubin>5 times the upper limit of normal(at each institution).2)Karnofsky score<30%.3)Documented invasive fungal infection before starting treatment.4)History of treatment by voriconazole or mycafungin.5)History of allergy or hypersensitivity to voriconazole or mycafungin.6)Not eligible for the study in the opinion of investigators

Design outcomes

Primary

Measure	Time frame
defervesce and survival rate after two and four weeks from starting treatment	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026